These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16231271)

  • 21. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up.
    Wang XY; Xu ZY; Ma JC; von Seidlein L; Zhang Y; Hao ZY; Han OP; Zhang YL; Tian MY; Ouyang PY; Zhang ZY; Han CQ; Xing ZC; Chen JC
    Vaccine; 2007 Jan; 25(3):446-9. PubMed ID: 16949710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis A booster vaccine in children after infant immunization.
    Kanra G; Yalcin SS; Kara A; Ozmert E; Yurdakök K
    Pediatr Infect Dis J; 2002 Aug; 21(8):727-30. PubMed ID: 12192159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis A vaccines and the elderly.
    Genton B; D'Acremont V; Furrer HJ; Hatz C; Louis Loutan
    Travel Med Infect Dis; 2006 Dec; 4(6):303-12. PubMed ID: 17098625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up.
    Sharapov UM; Bulkow LR; Negus SE; Spradling PR; Homan C; Drobeniuc J; Bruce M; Kamili S; Hu DJ; McMahon BJ
    Hepatology; 2012 Aug; 56(2):516-22. PubMed ID: 22371069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine.
    Bovier PA; Farinelli T; Loutan L
    Vaccine; 2005 Mar; 23(19):2424-9. PubMed ID: 15752828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose.
    Fiore AE; Shapiro CN; Sabin K; Labonte K; Darling K; Culver D; Bell BP; Margolis HS
    Pediatr Infect Dis J; 2003 Apr; 22(4):354-9. PubMed ID: 12690277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.
    Barkai G; Belmaker I; Givon-Lavi N; Dagan R
    Pediatr Infect Dis J; 2009 May; 28(5):391-3. PubMed ID: 19295466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children.
    López EL; Contrini MM; Mistchenko A; Kieffer A; Baggaley RF; Di Tanna GL; Desai K; Rasuli A; Armoni J
    Pediatr Infect Dis J; 2015 Apr; 34(4):417-25. PubMed ID: 25764099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study.
    Faridi MM; Shah N; Ghosh TK; Sankaranarayanan VS; Arankalle V; Aggarwal A; Sathiyasekaran M; Bhattacharya N; Vasanthi T; Chatterjee S; Choudhury J; Mitra M
    Indian Pediatr; 2009 Jan; 46(1):29-34. PubMed ID: 19179715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A; Ma J; Feng F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody titers and response to vaccination against hepatitis A and B in pediatric patients with portal hypertension.
    Rosa MN; Hessel G; Alves De Tommaso AM
    Acta Gastroenterol Latinoam; 2008 Sep; 38(3):187-93. PubMed ID: 18979898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of immunology effects between live attenuated hepatitis A vaccine and inactivated hepatitis A vaccine].
    Wang X; Meng Z; Li R
    Zhonghua Yi Xue Za Zhi; 2000 Jun; 80(6):422-4. PubMed ID: 11798797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to hepatitis A vaccine in HIV-positive patients.
    Weissman S; Feucht C; Moore BA
    J Viral Hepat; 2006 Feb; 13(2):81-6. PubMed ID: 16436125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations.
    Ceyhan M; Yildirim I; Kurt N; Uysal G; Dikici B; Ecevit C; Aydogan A; Koc A; Yasa O; Köseoğlu M; Onal K; Hacimustafaoglu M; Celebi S
    J Viral Hepat; 2008 Oct; 15 Suppl 2():69-72. PubMed ID: 18837839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children.
    Mitra M; Shah N; Faridi M; Ghosh A; Sankaranarayanan VS; Aggarwal A; Chatterjee S; Bhattacharyya N; Kadhe G; Vishnoi G; Mane A
    Hum Vaccin Immunother; 2015; 11(5):1147-52. PubMed ID: 26018443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina.
    Espul C; Benedetti L; Linares M; Cuello H; Lo Castro I; Thollot Y; Rasuli A
    Hum Vaccin Immunother; 2017 Nov; 13(11):2707-2712. PubMed ID: 28933624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1-11-year-old children.
    Roberton D; Marshall H; Nolan TM; Sokal E; Díez-Domingo J; Flodmark CE; Rombo L; Lewald G; Flor Jde L; Casanovas JM; Verdaguer J; Marés J; Esso DV; Dieussaert I; Stoffel M
    Vaccine; 2005 Oct; 23(43):5099-105. PubMed ID: 16055231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody response to hepatitis A immunization among human immunodeficiency virus-infected children and adolescents.
    Siberry GK; Coller RJ; Henkle E; Kiefner C; Joyner M; Rogers J; Chang J; Hutton N
    Pediatr Infect Dis J; 2008 May; 27(5):465-8. PubMed ID: 18382387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule.
    Connor BA; Blatter MM; Beran J; Zou B; Trofa AF
    J Travel Med; 2007; 14(1):9-15. PubMed ID: 17241248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.